Vorinostat is a targeted therapy medicine used in the treatment of Cutaneous T Cell Lymphoma (CTCL). Vorinostat is thought to work by reducing the growth and division of
lymphoma cells a process in the DNA which is involved in the gene regulation in these lymphomas.
Vorinostat is an oral capsule that you take every day.
Vorinostat may have the following side effects:
- Low blood counts
Vorinostat is approved by the TGA and the PBS for the following indications:
- CTCL as a third line treatment